Calliditas Therapeutics IPO Presentation Deck
Payor summary: perception of Nefecon
Clinical results from Phase 2b were strong and supportive of seeking approval based on the surrogate marker
Want to know what treatment to expect after the first 9 months, eager to see how long it might delay dialysis
and/or transplant
Didn't anticipate managing too differently - as long as the price remained within the broad range of $55 - 85k
per year. Restrictions are standard to specialty products and include:
• Prior authorization to label
Prescribed by nephrologist
Confirmation of IgAN diagnosis through renal biopsy
Step to ACE/ARB
• Tier 3 or 4 placement
Opportunity to strengthen Nefecon's value proposition by leveraging:
KOL guidance and endorsements
Health-economic benefit related to cost effectiveness of Nefecon vs. cost of dialysis/kidney transplant
• Additional clinical data related to the degree of sustained efficacy and tolerability post course of Nefecon
calliditas
June 2020
24View entire presentation